Polypharmacy in hematology and oncology patients and the resulting prevalence of potential drug-drug interactions (DDI)

被引：0
|
作者：
Metzke, B. [1 ]
Fink, G. [1 ]
Hieke, S. [2 ]
Jung, M. [3 ]
Hug, M. J. [4 ]
Engelhardt, M. [1 ]
机构：
[1] Univ Med Ctr Freiburg, Dept Hematol & Oncol, Freiburg, Germany
[2] Univ Med Ctr Freiburg, Inst Med Biometry & Med Informat, Freiburg, Germany
[3] Univ Freiburg, Inst Pharmaceut Sci, D-79106 Freiburg, Germany
[4] Univ Med Ctr Freiburg, Freiburg, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [1] Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy
    Bachmann, Paula
    Frahm, Niklas
    Debus, Jane Louisa
    Mashhadiakbar, Pegah
    Langhorst, Silvan Elias
    Streckenbach, Barbara
    Baldt, Julia
    Heidler, Felicita
    Hecker, Michael
    Zettl, Uwe Klaus
    [J]. PHARMACEUTICS, 2022, 14 (03)
  • [2] Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics
    Georgiev, Kaloyan D.
    Hvarchanova, Nadezhda
    Stoychev, Elitsa
    Kanazirev, Branimir
    [J]. SCIENCE PROGRESS, 2022, 105 (01)
  • [3] Polypharmacy and potential drug-drug interactions in emergency department patients in the Caribbean
    Dookeeram, Darren
    Bidaisee, Satesh
    Paul, Joanne F.
    Nunes, Paula
    Robertson, Paula
    Maharaj, Vidya Ramcharitar
    Sammy, Ian
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (05) : 1119 - 1127
  • [4] The Prevalence of Polypharmacy and Potential Drug-Drug Interactions among Iranian Cancer Patients: Which Patients were at Risk?
    Bazrafshani, Maliheh Sadat
    Pardakhty, Abbas
    Khandani, Behjat Kalantari
    Nasiri, Naser
    Moghaderi, Masoud
    Bazrafshani, Azam
    Mehmandoost, Soheil
    Beigzadeh, Amin
    Sharifi, Hamid
    [J]. CANCER INVESTIGATION, 2022, 40 (05) : 457 - 472
  • [5] The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan
    Nusair, Mohammad B.
    Al-Azzam, Sayer, I
    Arabyat, Rasha M.
    Amawi, Haneen A.
    Alzoubi, Karem H.
    Rabah, Asma A.
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2020, 28 (02) : 155 - 160
  • [6] The incidence of potential drug-drug interactions based on degree of polypharmacy
    Hirsh, EL
    Trimarco, TW
    Ward, MF
    Lee, D
    Nozzolillo, M
    Sama, AE
    [J]. ANNALS OF EMERGENCY MEDICINE, 2003, 42 (04) : S25 - S26
  • [7] Drug-drug interactions in oncology - prevalence and clinical relevance
    Hinnerkort, A.
    Liekweg, A.
    Muellerleile, U.
    Tiede, S.
    Bruellke, N.
    Jaehde, U.
    [J]. ONKOLOGIE, 2010, 33 : 1 - 1
  • [8] Prevalence of polypharmacy, drug-drug interactions, and inappropriate prescription in elderly patients with urological cancers
    Carballeira, Clara Castro
    Alda, Maria Ibanez
    Lanza, Maria
    Sanchez, Laura
    Sotelo, Marta
    Cacho, Diego
    Gomez, Borja
    Duran, Ignacio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Prevalence and predictors of potential drug-drug interactions
    Nikolic, Bozana
    Jankovic, Slobodan
    Stojanov, Oliver
    Popovic, Jovan
    [J]. CENTRAL EUROPEAN JOURNAL OF MEDICINE, 2014, 9 (02): : 348 - 356
  • [10] Drug-drug interactions in pediatric oncology patients
    Balk, T. E.
    van der Sijs, I. H.
    van Gelder, T.
    Janssen, J. J. B.
    van der Sluis, I. M.
    van Leeuwen, R. W. F.
    Engels, F. K.
    [J]. PEDIATRIC BLOOD & CANCER, 2017, 64 (07)
12345